Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfamethoxypyrazine is a long-acting sulfonamide antibacterial agent used in the treatment and prevention of bacterial infections and malaria. It acts as a competitive inhibitor of the bacterial enzyme dihydropteroate synthase, thereby blocking the incorporation of para-aminobenzoic acid (PABA) into folic acid. This inhibition disrupts folic acid synthesis in bacteria and protozoa such as Plasmodium species (malaria parasites), leading to impaired DNA and RNA synthesis. Sulfamethoxypyrazine is effective against a broad spectrum of gram-positive and gram-negative bacteria but resistance can occur. It has been used for respiratory tract infections, urinary tract infections, and malaria prophylaxis or treatment[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfamethoxypyrazine.